Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 261

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 261
---
. The fair value of    
 the warrants at the measurement date was $288. The short-term loan is subsequently measured   
 at its amortized cost. The Company recorded amortization of a discount as an interest expense 
 of $115 and $173 for the short-term loan, within financial expense line in the statements     
 of comprehensive loss for the year ended December 31, 2024 and 2023, respectively.            |

| As result of the cancellation of the Merger Agreement with 
 OceanTech those warrants were cancelled.                   |

| In April 2024, the Company received the grant from the                                                       
 Horizon 2020 Program in the amount of approximately $350 (approximately 327 Euro) and repaid the outstanding 
 balance of the loan received in August 2023 at the amount of $325.                                           |

| b. | In January 2024,                                                                              
 the Company received a $150 loan from several lenders, including from two directors of the    
 Company (the “January 2024 Loan”). Pursuant to the agreement reached in October               
 2024 (the “2024 Loan Amendment”) with the January 2024 Loan lenders, the January              
 2024 Loan Agreement have been extended until the earlier of an IPO consummation date or until 
 August 31, 2025 (the “Maturity Date”), and bear interest at 8% per annum until                
 maturity, commencing as of September 1, 2024. In addition, at the Maturity Date, the Company  
 will pay the January 2024 Loan lenders an aggregate risk premium equal to $50. Furthermore,   
 upon the occurrence of an IPO, the January 2024 Loan lenders will be granted warrants to      
 purchase such number of Ordinary Shares equal to two times the January 2024 Loan amount,      
 based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares  
 during the first five trading days as of such IPO consummation. As of December 31, 2024,      
 the loan balance, accrued interest and accrued risk premium was $169.                         |

| The risk premium was accounted as additional interest to                                    
 be paid upon maturity date, and the Company amortized such interest expense during the term 
 of the loan using the effective interest method.                                            |

| c. | Between October                                                                               
 2024 and November 2024, the Company entered into the October 2024 bridge loan agreements,     
 pursuant to which the Company obtained a